The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 26 December 2006, www.theannals.com, DOI 10.1345/aph.1H381.
 The Annals of Pharmacotherapy: Vol. 41, No. 1, pp. 79-85. DOI 10.1345/aph.1H381
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benson, J.
Right arrow Articles by Daugherty, K. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benson, J.
Right arrow Articles by Daugherty, K. K

NEUROLOGY

Botulinum Toxin A in the Treatment of Sialorrhea

Jennifer Benson, PharmD

Staff Pharmacist, Kroger Pharmacy, Frankenmuth, MI

Kimberly K Daugherty, PharmD BCPS

Associate Professor of Pharmacy Practice, Ferris State University, Grand Rapids, MI

Reprints: Dr. Daugherty, 2301 Rosewood Ave. SE, Grand Rapids, MI 49506-5268, fax 616/391-3783, daugherk{at}ferris.edu

OBJECTIVE: To review the efficacy and safety of botulinum toxin A (BTX) in the treatment of sialorrhea.

DATA SOURCES: A PubMed search and reference list review was performed to find clinical trials on BTX in the treatment of sialorrhea. The search was limited to English-language trials involving human subjects. Articles from 1965 to October 2006 were searched, using key words botulinum, botulinum toxin, Botox, sialorrhea, saliva, salivary gland, and drooling.

STUDY SELECTION AND DATA EXTRACTION: Reports of 15 studies were found on BTX in the treatment of sialorrhea in human subjects. Four controlled trials are presented in detail, and 11 uncontrolled studies are summarized.

DATA SYNTHESIS: One controlled trial found that BTX caused significant reductions in patients' severity and frequency of drooling compared with placebo. Another found significant saliva reductions in the treatment group receiving the highest dose of BTX but found no subjective improvement compared with the placebo group. A third study comparing BTX with placebo found significant improvements in subjective and objective measures of drooling in the treatment group. A fourth controlled trial found significant reductions from baseline levels of drooling after patients received BTX injections. Similar efficacy was found between the BTX and scopolamine treatment groups.

CONCLUSIONS: Evidence indicates that BTX is a safe and effective treatment for sialorrhea. More research is needed to determine the ideal dose, injection location, and technique of BTX injections.

Key Words: Botox, botulinum, botulinum toxin, drooling, saliva, salivary gland, sialorrhea

Published Online, December 26, 2006. www.theannals.com, DOI 10.1345/aph.1H381




homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.